Skip to main content
COGTCogent Biosciences, Inc.Sell4.8·$27.44
SellModerate Confidence
Investment thesis

Cogent Biosciences is a pre-revenue biotech whose value rests on one pipeline program; analysts see 53.5% upside, but quality is weak, losses persist and the shares remain in a downtrend.

Thesis pillars

  • Analyst Target Upside→Stable
  • Single Program Dependence↓Deteriorating
  • Persistent Quarterly Losses↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 8, 2026, based on the 10-K filed Feb 17, 2026

Full reasoning →

Open full analysis

Cogent Biosciences, Inc. (COGT) Stock Analysis

Falling Knife setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $27.44: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 2.40; Below-average business quality.

Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic Mastocytosis and GIST. The company submitted its first NDA for NonAdvSM in December 2025 and initiated the GIST NDA submission in January 2026; a U.S. commercial... Read more

$27.44+77.0% A.UpsideScore 4.8/10#188 of 240 Biotechnology
QualityF-score4 / 9FCF yield-4.01%
Stop $26.41Analyst target $48.56(−13% haircut)A.R:R 5.7:1
Analyst consensus$55.82+103.4%11 analysts with price targets
$48.56Analyst target
$27.44price
$55.82mean
$61

Sell if holding. Engine safety override at $27.44: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 2.40; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Score 4.8/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 91d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

10-K grounded · weekly refresh

About Cogent Biosciences, Inc.

About Cogent Biosciences, Inc.

Cogent Biosciences reported positive top-line results from all three registrational trials for bezuclastinib in 2025: SUMMIT (NonAdvSM), APEX (AdvSM), and PEAK (GIST). The company submitted its first NDA in December 2025 (NonAdvSM), initiated the GIST NDA submission in January 2026, and targets an AdvSM NDA in the first half of 2026. The FDA granted Breakthrough Therapy Designation for bezuclastinib in NonAdvSM in October 2025 and for second-line GIST in January 2026. A U.S. commercial launch is planned for the second half of 2026.

Cogent Biosciences has no product revenue; the company funds operations through equity financing and plans to commercialize bezuclastinib in SM and GIST following regulatory approval. Bezuclastinib is licensed exclusively from Plexxikon Inc., a Daiichi Sankyo subsidiary, under a 2020 license agreement that requires tiered royalties ranging from low- to high-single-digit percentages on annual net sales, aggregate development milestone payments of up to $7.5 million (the first $2.5 million paid in June 2022, $5.0 million triggered in Q4 2025), and regulatory milestones of up to $25.0 million (an additional $15.0 million may become payable within twelve months). The company is building an internal commercial organization to market bezuclastinib in the United States. Early-stage pipeline assets include CGT4859 (FGFR2/3 inhibitor, Phase 1 enrolling), CGT4255 (CNS-penetrant ErbB2 inhibitor, Phase 1 initiated Q4 2025), and CGT6297 (PI3Kα inhibitor, IND submitted Q4 2025). Preclinical KRAS and JAK2 V617F programs have IND submissions planned for 2026.

Show full overview

Cogent's valuation is essentially a single NDA binary: bezuclastinib is the only program at a regulatory stage and the source of all planned near-term revenue. The PEAK trial demonstrated median PFS of 16.5 months versus 9.2 months for sunitinib monotherapy in second-line GIST, reducing the risk of progression or death by 50%. However, there is no guarantee of regulatory approval for any indication, and even an approved bezuclastinib would face competition from Blueprint Medicines' avapritinib (a Sanofi company) and Novartis AG's midostaurin in AdvSM, with market size estimates inherently uncertain for rare-disease indications.

See also: Healthcare · Biotechnology

From Cogent Biosciences, Inc.'s most recent 10-K filing, extracted June 9, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 13, 2026

Recent Developments — Cogent Biosciences, Inc.

Latest item Nov 13, 2026 · Generated 2026-11-17T12:02:25Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Feb 16, 202791d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Pipeline: bezuclastinib program
Quality below floor (1.5 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-21.6
Mkt Cap$4.8B
EV/EBITDA-10.2
Profit Mgn0.0%
ROE-99.6%
Rev Growth—
Beta0.34
DividendNone
Analysts with ratings18

Quality Signals

Piotroski F4/9

Options Flow

P/C2.40bearish
IV154%elevated

Concentration Risks(10-K Item 1A)

  • HIGHpipelinebezuclastinib program
    10-K Item 1A: 'Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
1.0
Volume
1.4
Rsi
3.5
Volume distribution (falling OBV)Below 200-MA, MA slope -2.9%/30d — confirmed downtrend

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Moat
4.0
Piotroski F
4.4
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatQuality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.0
Value Rank
5.0
Growth Rank
5.0

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
1.3
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0
News Activity
5.0
Earnings concerns: 2B/2M
GatesMomentum 1.4<4.5Death cross (50MA < 200MA)A.R:R 5.7 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 91d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Speculative
RSI
36 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $27.23Resistance $34.04

Price Targets

$26
$49
A.Upside+77.0%
A.R:R5.7:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (1.5 < 4.0)
! momentum at 1.4 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
M
M
2/4 beats
Next Earnings2027-02-16 (91d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is COGT stock a buy right now?

Sell if holding. Engine safety override at $27.44: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 2.40; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Prior stop was $26.41. Score 4.8/10, moderate confidence.

What is the COGT stock price target?

Analyst target: $48.56 (+77.0% upside). Prior stop was $26.41. Stop-loss: $26.41.

What are the risks of investing in COGT?

Concentration risk — Pipeline: bezuclastinib program; Quality below floor (1.5 < 4.0).

Is COGT overvalued or undervalued?

Cogent Biosciences, Inc. trades at a P/E of N/A (forward -21.6). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about COGT?

18 analysts rate COGT, with a consensus score of 4.3/5. 11 analysts publish price targets averaging $56.

What does Cogent Biosciences, Inc. do?Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic...

Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic Mastocytosis and GIST. The company submitted its first NDA for NonAdvSM in December 2025 and initiated the GIST NDA submission in January 2026; a U.S. commercial launch in the second half of 2026 is planned pending regulatory approval. Bezuclastinib is exclusively in-licensed from Plexxikon Inc. with mid- to high-single-digit royalties on net sales.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · ASND (Ascendis Pharma A/S) · HALO (Halozyme Therapeutics, Inc.) · MGTX (MeiraGTx Holdings plc) · PHAT (Phathom Pharmaceuticals, Inc.)
Home › Stocks › COGT

Latest news

Latest News

Fiscal.ai4d ago
Fiscal.ai8d agoAnalyst
Benzinga8d agoAnalyst
Fiscal.ai12d ago
Benzinga12d agoEarnings
Benzinga12d agoFda Decision
Benzinga12d agoEarnings
Fiscal.ai21d ago
Benzinga27d ago
Benzinga36d ago
Benzinga46d ago
Benzinga76d agoProduct
Benzinga78d ago
Benzinga92d agoAnalyst
Benzinga97d agoAnalyst
Benzinga99d ago
Benzinga99d ago
Benzinga102d ago
Benzinga140d agoFda Decision
Benzinga158d agoProduct
Loading more...